ABSTRACT:
The use of Fixed dose combinations (FDCs) of antitubercular drugs in the short course chemotherapy of tuberculosis is
being promoted internationally. However poor bioavailability of rifampicin has been perceived as a major bottleneck in successful treatment of tuberculosis. It perhaps is amongst one of the contributory factor which may lead to increasing resistance to anti-tubercular drugs. The present article critically focuses on various probable physical and/or chemical reasons responsible for poor/variable bioavailability of rifampicin in FDC and suggests the various approaches which may be successfully employed to overcome the aforementioned problems associated with rifampicin in FDCs.
Cite this article:
Satish Balkrishna Bhise, Sevukarajan Mookkan. Poor Bioavailability of Rifampicin- A Global Emergency. Research J. Pharm. and Tech. 1(3): July-Sept. 2008; Page 155-160.
Cite(Electronic):
Satish Balkrishna Bhise, Sevukarajan Mookkan. Poor Bioavailability of Rifampicin- A Global Emergency. Research J. Pharm. and Tech. 1(3): July-Sept. 2008; Page 155-160. Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2008-1-3-43